These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c. Hajer GR; van der Graaf Y; Bots ML; Algra A; Visseren FL; Eur J Clin Invest; 2009 Aug; 39(8):680-8. PubMed ID: 19453647 [TBL] [Abstract][Full Text] [Related]
29. Lipoprotein patterns in adult cystic fibrosis: a cause for concern or marker for survival? Worgall TS Respirology; 2010 Jul; 15(5):731-2. PubMed ID: 20653919 [No Abstract] [Full Text] [Related]
30. Malondialdehyde-modified LDL to HDL-cholesterol ratio reflects endothelial damage. Sugiura T; Dohi Y; Yamashita S; Yamamoto K; Tanaka S; Wakamatsu Y; Kimura G Int J Cardiol; 2011 Mar; 147(3):461-3. PubMed ID: 21296433 [No Abstract] [Full Text] [Related]
31. Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. Hadaegh F; Harati H; Ghanbarian A; Azizi F Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):571-7. PubMed ID: 16874147 [TBL] [Abstract][Full Text] [Related]
32. [Role of biochemical risk factors and markers for the risk of atherosclerosis]. Montagnana M; Lippi G; Salvagno GL; Franchini M; Targher G; Guidi GC Recenti Prog Med; 2008 Apr; 99(4):215-22. PubMed ID: 18595637 [TBL] [Abstract][Full Text] [Related]
33. LDL-cholesterol as a determinant of coronary heart disease. Hunninghake D Clin Ther; 1990; 12(5):370-5; discussion 369. PubMed ID: 2268861 [TBL] [Abstract][Full Text] [Related]
35. [Evaluation of selected risk factors of atherosclerosis in children with type 1 diabetes mellitus and hypercholesterolemia]. Muchacka-Bianga M; Deja G; Jarosz-Chobot P; Małecka-Tendera E; Kalina M; Grychtoł M Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(1):25-30. PubMed ID: 16704858 [TBL] [Abstract][Full Text] [Related]
36. The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS. Howard WJ Nutr Metab Cardiovasc Dis; 2010 Jun; 20(5):295-300. PubMed ID: 20556890 [TBL] [Abstract][Full Text] [Related]
37. Influence of HDL cholesterol on preclinical carotid atherosclerosis in familial hypercholesterolemia. Junyent M; Cofán M; Núñez I; Gilabert R; Zambón D; Ros E Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1107-13. PubMed ID: 16556855 [TBL] [Abstract][Full Text] [Related]
38. Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease. Faergeman O J Intern Med; 2006 May; 259(5):434-6. PubMed ID: 16629848 [No Abstract] [Full Text] [Related]
39. [Estimation of selected parameters antioxidant barrier and lipid parameters in children with atherosclerosis risk factors]. Sierakowska-Fijałek A; Fijałkowski P; Błaszczyk J; Baj Z; Stepień M; Wosik-Erenbek M; Rysz J Pol Merkur Lekarski; 2008 Jan; 24(139):14-7. PubMed ID: 18634244 [TBL] [Abstract][Full Text] [Related]
40. Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients. Soran H; France MW; Kwok S; Dissanayake S; Charlton-Menys V; Younis NN; Durrington PN Ann Clin Biochem; 2011 Nov; 48(Pt 6):566-71. PubMed ID: 22006975 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]